Key result
Dual antithrombotic therapy cuts major bleeding versus triple therapy in post-PCI atrial fibrillation.
Why the study?
Does dual antithrombotic therapy with a NOAC and a P2Y12 inhibitor reduce bleeding complications compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Does dual antithrombotic therapy with a NOAC and a P2Y12 inhibitor reduce bleeding complications compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Dual antithrombotic therapy comprising a NOAC and a P2Y12 inhibitor reduces bleeding risk compared to triple antithrombotic therapy and is recommended for most patients with atrial fibrillation following PCI.
Answers are grounded in this paper and cite their sources.
May favor dual NOAC-P2Y12 therapy to reduce bleeding in AF-PCI; leaves open optimal regimens and durations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Undas et al. (2020) conducted a review in Atrial fibrillation undergoing percutaneous coronary intervention. Dual antithrombotic therapy (NOAC + P2Y12 inhibitor) vs. Triple antithrombotic therapy (VKA + aspirin + P2Y12 inhibitor) was evaluated. Dual antithrombotic therapy with a NOAC and P2Y12 inhibitor lowers the risk of major bleeding and is preferred over triple therapy for the majority of PCI patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: